covid-19 vaccination in peru covid-19 vaccination in peru the covid-19 vaccination program in peru is the national vaccination strategy to protect the population against sars-cov-2 employing vaccines developed for the covid-19 pandemic in peru. vaccination began on 9 february 2021, after three days of arrival of first vaccines. on a nation message, the head of state francisco sagasti confirmed the purchase of 38 millions of vaccines, being one million of vaccines for health personnel. part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal covid-19 vaccination in peru vaccine administered by departments vaccine administered by provincesdate9 february 2021 (2021-02-09)locationperucausecovid-19 pandemic in perutargetimmunisation of peruvians against covid-19organised byministry of health of peruwebsitegobierno del perú timeline arrival of the first vaccines on 7 february 2021 at 19:54 h (utc−5), 300,000 vaccines lot of sinopharm coming from china arrived at the airport jorge chávez. this event was overseen by the president, francisco sagasti. shortly after, the head of state reported that on 14 february a remaining lot 700,000 vaccines will also arrive to the country. on 8 february 2021, a thousand police officers were reported to guard the warehouse of national center for the supply of strategic health resources (cenares, acronym in spanish). vaccine distribution according to the government of peru, the vaccination is predicted in three phases. stage people included 1 health sector personnel national police armed forces general corps of volunteer firefighters peruvian red cross serenazgo (watchman unit) staff of the national institute of civil defense (indeci, acronym in spanish) health-related science students. board members of the 2021 national elections 2 people over 60 years and with comorbidity. native or indigenous population prison staff 3 people over 18 years of age public opinion according to the study presented by ipsos, a french sociological and market research company, the acceptance of the vaccine in the peruvian population was below 50% until january 2021 due to an environment of mistrust in the management of the vaccination and management of the pandemic during the government of martín vizcarra and francisco sagasti. as of february 2021, the period that begins the vaccination process, the study revealed a slow and steady increase in the acceptance of the covid-19 vaccine. question: "do you want to be vaccinated, do you not want to be vaccinated or have you already been vaccinated? optionmonth i do want to get vaccinated i don't want to get vaccinated i already got vaccinated not precise source aug 2020* 75% 22% 0% 3% dec 2020* 57% 40% 0% 3% jan 2021* 48% 48% 0% 4% feb 2021* 59% 35% 0% 6% mar 2021** 60% 33% 0% 7% may 2021* 63% 30% 4% 3% note: (*) it was asked how "if right now a vaccine approved by the ministry of health and free to prevent the covid-19, do you? would you be vaccinated or not vaccinated? note 2: (**) he wondered how "if tomorrow it's your turn for the covid-19 vaccine, would you or would you not get the vaccine?" vaccines on order vaccine name doses progress quantity approval deployment last delivery sinopharm bibp two phase iii clinical trials 6 million 6 january 2021 7 february 2021 5 june 2021 pfizer–biontech two phase iii clinical trials 20,5 million 9 february 2021 3 march 2021 1 july 2021 12 million 6 may 2021 35 million 17 september 2021 oxford–astrazeneca and pfizer–biontech (by covax facility) two phase iii clinical trials 13,2 million 18 september 2020 10 march 2021 3 june 2021 oxford–astrazeneca two phase iii clinical trials 14 million 6 january 2021 not yet not yet johnson & johnson one phase iii clinical trials pending 8 july 2021 not yet not yet sputnik v two phase iii clinical trials 20 million 20 july 2021 not yet not yet moderna two phase iii clinical trials 20 million 17 september 2021 not yet not yet chronology of the doses arrived in peru no. vaccine name quantity arrival date source(s) 1 sinopharm bibp 300,000 7 february 2021 2 sinopharm bibp 700,000 13 february 2021 3 pfizer–biontech 50,000 3 march 2021 4 pfizer–biontech (by covax facility) 117,000 10 march 2021 5 pfizer–biontech 50,000 10 march 2021 6 pfizer–biontech 50,000 17 march 2021 7 pfizer–biontech 50,310 24 march 2021 8 pfizer–biontech 49,140 31 march 2021 9 pfizer–biontech 200,070 7 april 2021 10 pfizer–biontech 200,700 14 april 2021 11 oxford-astrazeneca (by covax facility) 276,000 18 april 2021 12 pfizer–biontech 200,700 21 april 2021 13 pfizer–biontech 200,000 28 april 2021 14 pfizer–biontech 350,000 6 may 2021 15 pfizer–biontech 350,000 7 may 2021 16 pfizer–biontech 700,000 13 may 2021 17 pfizer–biontech 395,000 17 may 2021 18 pfizer–biontech 395,000 20 may 2021 19 pfizer–biontech 396,630 24 may 2021 20 pfizer–biontech 395,460 26 may 2021 21 oxford-astrazeneca (by covax facility) 511,200 29 may 2021 22 pfizer–biontech 251,550 31 may 2021 23 sinopharm bibp 700,000 2 june 2021 24 pfizer–biontech (by covax facility) 468,000 3 june 2021 25 pfizer–biontech 250,380 3 june 2021 26 pfizer–biontech 242,190 4 june 2021 27 sinopharm bibp 300,000 5 june 2021 28 pfizer–biontech 496,080 10 june 2021 29 pfizer–biontech 497,250 17 june 2021 30 pfizer–biontech 497,250 24 june 2021 31 pfizer–biontech (united states donation) 1,002,000 29 june 2021 32 pfizer–biontech 497,250 1 july 2021 33 pfizer–biontech (united states donation) 998,000 7 july 2021 34 sinopharm bibp 614,400 10 july 2021 35 sinopharm bibp 385,600 11 july 2021 36 pfizer–biontech 281,970 15 july 2021 37 pfizer–biontech 886,860 22 july 2021 38 pfizer–biontech 936,000 26 july 2021 39 pfizer–biontech 196,560 30 july 2021 40 sinopharm bibp 1,000,000 1 august 2021 41 oxford–astrazeneca (spain donation) 101,760 4 august 2021 42 pfizer–biontech 475,020 5 august 2021 43 pfizer–biontech 569,790 12 august 2021 44 sinopharm bibp 1,000,000 15 august 2021 45 pfizer–biontech 594,360 20 august 2021 46 sinopharm bibp 614,400 21 august 2021 47 sinopharm bibp 385,600 22 august 2021 48 pfizer–biontech 540,540 26 august 2021 49 sinopharm bibp 1,000,000 29 august 2021 50 oxford–astrazeneca (canada donation) 35,100 2 september 2021 51 pfizer–biontech 662,220 3 september 2021 52 sinopharm bibp 2,000,000 4 september 2021 53 pfizer–biontech 748,800 6 september 2021 54 oxford–astrazeneca (by covax facility) 362,400 8 september 2021 55 sinopharm bibp 2,862,500 10 september 2021 56 sinopharm bibp 3,342,600 11 september 2021 57 sinopharm bibp 794,900 12 september 2021 58 pfizer–biontech 748,800 13 september 2021 59 oxford–astrazeneca (ecuador donation) 336,000 13 september 2021 60 oxford–astrazeneca (by covax facility) 146,400 14 september 2021 dose count and statistics vaccine name quantity total % of population targetpopulation % of population population(est. 2020) one dose two dose one dose two dose sinopharm bibp 16,000,000 33,761,600 123.92% 61.96% 27,244,203 103.48% 51.74% 32,625,948 pfizer-biontech 15,992,740 oxford-astrazeneca 1,768,860 vaccines in trial stage vaccine type (technology) phase i phase ii phase iii sinopharm bibp inactivated completed completed completed pfizer–biontech rna completed completed completed oxford–astrazeneca viral vector completed completed completed janssen viral vector completed completed in progress curevac rna completed completed in progress statistics by department covid-19 vaccination by department september 15, 2021 (utc−5) departmentand autonomous province first dose second dose cumulativedose population(est. 2020) total % of pop. total % of pop. peru 12,391,748 37.98% 8,933,405 27.38% 21,325,153 32,625,948 amazonas 136,284 31.93% 87,684 20.54% 223,968 426,806 ancash 462,904 39.21% 335,213 28.39% 798,117 1,180,638 apurimac 173,013 40.17% 109,310 25.38% 282,323 430,736 arequipa 631,543 42.17% 461,804 30.84% 1,093,347 1,497,438 ayacucho 213,214 31.91% 132,005 19.75% 345,219 668,213 cajamarca 476,824 32.80% 318,320 21.90% 795,144 1,453,711 callao province 579,182 51.26% 435,523 38.55% 1,014,705 1,129,854 cusco 444,355 32.74% 333,979 24.61% 778,334 1,357,075 huancavelica 127,322 34.85% 94,532 25.88% 221,854 365,317 huanuco 206,599 27.17% 128,563 16.91% 335,162 760,267 ica 400,451 41.06% 265,235 27.20% 665,686 975,182 junin 508,964 37.38% 397,651 29.21% 906,615 1,361,467 la libertad 661,806 32.82% 443,839 22.01% 1,105,645 2,016,771 lambayeque 386,439 29.48% 277,086 21.14% 663,525 1,310,785 lima 444,891 46.65% 295,779 31.01% 740,670 953,715 lima province 4,456,211 46.06% 3,425,830 35.41% 7,882,041 9,674,755 loreto 215,317 20.95% 147,365 14.34% 362,682 1,027,559 madre de dios 40,197 23.13% 26,153 15.05% 66,350 173,811 moquegua 80,252 41.64% 61,156 31.73% 141,408 192,740 pasco 112,817 41.49% 81,992 30.15% 194,809 271,904 piura 625,908 30.56% 422,917 20.65% 1,048,825 2,047,954 puno 274,952 22.21% 150,940 12.19% 425,892 1,237,997 san martin 281,842 31.33% 189,418 21.05% 471,260 899,648 tacna 198,557 53.52% 147,786 39.84% 346,343 370,974 tumbes 93,790 37.29% 58,474 23.25% 152,264 251,521 ucayali 158,114 26.84% 104,851 17.80% 262,965 589,110 progress of the vaccination campaign covid-19 vaccination progress in peruestimated population to be vaccinated: 27,244,203 people 45.5% complete (inoculated with first dose) 32.8% complete (inoculated with second dose) date first dose second dose cumulativedose total variation % of pop. total variation % of pop. 9-feb-21 3,842 3,842 0.01% 0 0 0.00% 3,842 15-feb-21 110,792 106,9500.41% 0 0 0.00% 110,792 1-mar-21 321,851 211,059 1.18% 0 0 0.00% 321,851 15-mar-21 430,874 109,023 1.58% 173,578 173,578 0.64% 604,452 1-apr-21 662,463 231,589 2.43% 377,945 204,367 1.39% 1,040,408 15-abr-21 743,077 80,614 2.73% 544,887 166,942 2.00% 1,287,964 1-may-21 1,127,587 384,510 4.14% 687,606 142,719 2.52% 1,815,193 15-may-21 1,815,080 687,493 6.66% 825,828 138,222 3.03% 2,640,908 1-jun-21 2,984,620 1,169,540 10.96% 1,332,284 506,456 4.89% 4,316,904 15-jun-21 3,829,456 844,836 14.06% 2,236,998 904,714 8.21% 6,066,454 1-jul-21 4,612,161 782,705 16.93% 3,287,742 1,050,744 12.07% 7,899,903 15-jul-21 6,474,729 1,862,568 23.77% 3,845,047 557,305 14.11% 10,319,776 1-aug-21 8,035,796 1,561,067 29.50% 5,287,167 1,442,120 19.41% 13,322,963 15-aug-21 9,215,626 1,023,435 33.83% 6,920,113 1,437,778 25.40% 16,135,739 1-sep-21 10,519,572 1,184,432 38.61% 8,314,606 1,191,212 30.52% 18,834,178 15-sep-21 12,391,748 1,747,180 45.48% 8,933,405 495,538 32.79% 21,325,153 demographics vaccination by sex and age, registered on september 15, 2021 year group male female first dose second dose cumulativedose population(est. 2020) one dose two dose one dose two dose total % of pop. total % of pop. total 5,883,925 4,205,383 6,507,830 4,728,027 12,391,755 37.98% 8,933,410 27.38% 21,325,165 32,625,948 0-9 0 0 0 0 0 0.00% 0 0.00% 0 5,384,070 10-19 1 2 1 2 2 0.00% 4 0.00% 6 5,206,372 20-29 268,104 165,164 276,265 147,666 544,369 10.07% 312,830 5.79% 857,199 5,403,670 30-39 902,481 227,252 1,048,431 295,265 1,950,912 38.78% 522,517 10.39% 2,473,429 5,031,117 40-49 1,469,356 916,504 1,618,837 1,057,378 3,088,193 73.82% 1,973,882 47.19% 5,062,075 4,183,147 50-59 1,323,836 1,122,048 1,433,083 1,243,231 2,756,919 84.13% 2,365,279 72.18% 5,122,198 3,277,134 60-69 991,384 906,676 1,065,272 983,839 2,056,656 92.59% 1,890,515 85.11% 3,947,171 2,221,241 70-79 598,883 560,388 653,300 614,198 1,252,183 98.45% 1,174,586 92.35% 2,426,769 1,271,842 80+ 329,878